Digital
On AI and computational support of biochemistry, with Alan R...
Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Digital
Regulators open the AI floodgates in life sciences
In 2026, biopharma will move from proving AI works to proving it can be trusted at scale.
R&D
GLP-1s in CKD: Evidence, market leadership, and key insights...
At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight.
Sales & Marketing
The rise of NP/PA influence: Why and how pharma marketing st...
The rise of NP/PA influence is not a passing trend; it is a structural realignment of US healthcare. These clinicians are the connective tissue.
Sales & Marketing
Sponsored
The AI imperative: Establishing the standard for modern clin...
The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
